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ABSTRACT 
Lymphocytes from normal subjects and patients with B-chronic lymphocytic 
leukemia (B-CLL) show functional responses to extracellular ATP characteristic 
of the P2X7 receptor.  These responses include opening of a cation selective 
channel/pore which allows entry of the fluorescent dye, ethidium+ and activation 
of a membrane metalloprotease which sheds the adhesion molecule L-selectin.  
In this thesis, the surface expression of P2X7 receptors was measured in 
normal leucocytes, platelets and B-CLL lymphocytes and compared with their 
functional responses.   Monocytes showed 4-5 fold greater expression of P2X7 
than B-, T- and NK- lymphocytes, while P2X7 expression on neutrophils and 
platelets was weak.  All cell types demonstrated abundant intracellular 
expression of this receptor. All 12 subjects with B-CLL expressed surface P2X7 
at about the same level as for B-lymphocytes from normal subjects.  P2X7 
function, measured by ATP-induced uptake of ethidium, correlated closely with 
surface expression of this receptor in normal and B-CLL lymphocytes and 
monocytes. However, the ATP-induced uptake of ethidium into the malignant B-
lymphocytes in 3 patients was low or absent.  The lack of P2X7 function in these 
B-lymphocytes was confirmed by the failure of ATP to induce Ba2+ uptake into 
their lymphocytes. This lack of function of the P2X7 receptor resulted in a failure 
of ATP-induced shedding of L-selectin, an adhesion molecule which directs the 
recirculation of lymphocytes from blood into the lymph node.  
To study a possible genetic basis of non-functional P2X7 receptor, we 
sequenced DNA coding for the carboxyl terminal tail of P2X7.  In 33 of 130 
normal subjects a heterozygous nucleotide substitution (1513A→C) was found 
while 3 subject carried the homozygous substitution which codes for glutamic 
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acid to alanine at amino acid position 496.  Surface expression of P2X7 on 
lymphocytes was not affected by this 496Glu→Ala polymorphism demonstrated 
both by confocal microscopy and immunofluorescent staining.  Monocytes and 
lymphocytes from the 496Glu→Ala homozygote subject expressed non-
functional receptor while heterozygotes showed P2X7 function which was half 
that of wild type P2X7.  Results of transfection experiments showed the mutant 
P2X7 receptor was non-functional when expressed at low receptor density but 
regained function at a high receptor density.  This density-dependence of 
mutant P2X7 function was also seen on differentiation of fresh monocytes to 
macrophages with interferon-γ which upregulated mutant P2X7 and partially 
restored its function. P2X7-mediated apoptosis of lymphocytes was impaired in 
homozygous mutant P2X7 compared with wild type. The data suggest that the 
glutamic acid at position 496 is required for optimal assembly of the P2X7 
receptor. 
Apart from the 496Glu→Ala polymorphism, three other single nucleotide 
polymorphisms, 155His→Tyr, 348Ala→Thr and 568Ile→Asn were also found in 
the P2X7 receptor. The site directed mutant cDNA were generated for all 3 
polymorphisms and transfected into HEK293 cells to study the impact of these 
polymorphisms on P2X7 function. Results suggested that Ile568 is important for 
P2X7 protein trafficking to cell surface.  Further study of these two loss-of-
function polymorphisms (496Glu→Ala and 568Ile→Asn) may help better 
understanding of the functional domains in the P2X7 receptor and its role in 
CLL, lymphoma and infectious diseases. 
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Conclusions: 
1. P2X7 receptor is expressed in human leukocytes, including lymphocytes, 
natural killer cells as well as monocytes, on both surface and intracellular 
locations. 
2. Both the expression and function of P2X7 are highly variable between in 
human individuals.  Non-functional P2X7 receptors are found in some 
subjects, including both normal subjects and CLL patients, and are often 
associated with defects in ATP-induced cytotoxicity and L-selectin 
shedding. 
3. Two single nucleotide polymorphisms (SNPs), 496Glu→Ala and 
568Ile→Asn, are found at low frequency in the human population and lead 
to the loss-of-function of P2X7.  Both permeabllity function and the 
downstream effects mediated by P2X7 are affected by these two SNPs.  
The mechanisms for the loss-of-function differs between the two 
polymorphisms. 
 
 
 
 
Key words: P2X7 receptor, single nucleotide polymorphism, chronic 
lymphocytic leukemia, ATP-induced ethidium uptake 
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ABBREVIATIONS 
The abbreviations listed below are frequently used in the thesis. 
α,β-meATP  α,β-methylene adenosine 5'-triphosphate 
β,γ-meATP β,γ-methylene ATP 
µM  10-6 M 
2-MeSADP  2-methylthio- adenosine 5'-diphosphate 
2-meSATP  2-methylthio- adenosine 5'-triphosphate 
7-AAD   7-amino-actinomycin D 
A2P5P adenosine 2’,3’-diphosphate 
A3P5P adenosine 3’,5’-diphosphate 
A3P5PS adenosine 3’-phosphate 5’-phosphosulfate 
AC adenylate cyclase 
ADP adenosine 5'-diphosphate 
AMP adenosine 5'-monophosphate 
Ap4A P1, P4-diadenosine tetraphosphate 
ATP  adenosine 5'-triphosphate 
ATP-αS adenosine 5’-O-(1-thiotriphosphate) 
ATP-γS adenosine 5’-O-(3-thiotriphosphate) 
BAPTA-AM 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
tetrakis (acetoxymethyl ester) 
BSA  bovine serum albumin 
BzATP  3'-O-(4-benzoyl)benzoyl-adenosine 5'-triphosphate 
cAMP adenosine 3’, 5’-cyclic monophosphate 
cDNA  complementary DNA 
CLL  chronic lymphocytic leukemia 
DAG diacylglycerol 
dATP  3'-deoxy adenosine 5'-triphosphate 
EC50 concentration of a drug that produce 50% of the maximum 
response 
ECL  enhanced chemiluminescence 
EDTA  ethylenediaminetetraacetic acid 
EGTA ethylene glycol-bis (ß-aminoethyl ether) N,N,N',N'-
tetraacetic acid 
Fig  figure 
 XIII
FITC  fluorescein isothiocyanate 
Fura-2 AM  Fura-2 acetoxymethyl ester 
Fura-Red   Fura Red acetoxymethyl ester 
HEPES  N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
HMA  5-(N,N-hexamethylene)-amiloride 
HRP  horseradish peroxidase 
IC50 concentration of a drug that produce 50% of the maximum 
inhibition 
ICE IL-1β converting enzyme 
IFN-γ  Interferon-γ 
IP3 inositol 1,4,5-trisphosphate 
KN-62 1-(N,O-bis(5-isoquinoline sulfonyl)N-methyl-L-tyrosyl)-4-
phenylpiperazine 
LPS lipopolysaccharide 
mAb  monoclonal antibody 
MAPK mitogen-activated protein kinase 
mM  10-3 M 
mRNA message RNA 
MRS2220 cyclic pyridoxine-α4,5,-monophosphate-6-azo-phenyl-
2’,5’disulfonate 
NECA N-ethylcarboxamidoadenosine 
nM  10-9 M 
NMDG N-methyl-D-glucamine 
NOS nitric oxide synthase 
OxATP  adenosine 5'-triphosphate-2',3'-dialdehyde 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PCR  Polymerase Chain Reaction 
PKC protein kinase C 
PLCβ phospholipase Cβ 
PLD  phospholipase D 
PMA  phorbol 12-myristate 13-acetate 
PPADS pyridoxal phosphate-6-azophenyl-2’,4’-disulfonic acid 
PTX  pertussis toxin 
R.T.  room temperature 
Ro 31-9790 N-2-((2s)-(hydroxycarbamoyl)4-methylvaleryl)-N-1,3-
dimethyl-L-valinamide 
 XIV
ROI reactive oxygen intermediate 
RT-PCR   Reverse-Transcription Polymerase Chain Reaction 
SDF-1α  stromal cell-derived factor 1α 
SDS  sodium dodecyl sulfate 
SNP single nucleotide polymorphism 
Suramin 8-(3-benzamido-4-methylbenzamido)-naphthalene-1,3,5-
trisulfonic acid 
TM transmembrane 
TMA  trimethylammonium chloride 
TNF-α  Tumour Necrosis Factor-α 
TNP-ATP 2’(3’)-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate 
TNP-GTP 2’(3’)-O-(2,4,6-trinitrophenyl) guanosine 5’-triphosphate 
UDP uridine 5’-diphosphate 
UTP uridine 5’-triphosphate 
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